Archive: April 2024

The Role of Noncovalent BTK Inhibitors in the Era of Covalent BTK Inhibitors

Abstract: Despite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some […]

Immunotherapy in the Treatment of Advanced or Recurrent Endometrial Cancer

Abstract: The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical […]

Letter From the Editor: Empty Nest

Spring is here, which means graduation time, among other things. My youngest daughter is about to graduate from college and will be home briefly for the […]

Highlights in Prostate Cancer From the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

January 25-27, 2024 • San Francisco, California and Virtual Abiraterone Plus Olaparib Improves Outcomes in Metastatic Castration-Resistant Prostate Cancer A combination of abiraterone and olaparib (Lynparza, […]

Thrombotic Complications of Influenza and COVID-19 Infections

H&O  How often do influenza and COVID-19 lead to thrombotic complications? PN  The true incidence of thrombotic complications with influenza and COVID-19 is unclear. A study […]

Coordination Between the FDA and the US Patent and Trademark Office

H&O  What is the Executive Order on Promoting Competition in the American Economy and how does it relate to coordination between the FDA and the USPTO? […]

Six-Year Update of the ELEVATE-TN Study on Acalabrutinib

H&O  Could you describe the impetus for and design of the ELEVATE-TN trial? JS  The ELEVATE-TN study was conducted to seek regulatory authorization for acalabrutinib (Calquence, […]

Back to Archive